Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
21 November 2023 - 10:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 20, 2023
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Novo Nordisk A/S –
Share repurchase programme
Bagsværd,
Denmark, 20 November 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with
Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation
(EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme
of up to DKK 30 billion to be executed during a 12- month period beginning 1 February 2023.
Under the programme initiated
6 November 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 4.1 billion in the period from 7 November 2023 to 29 January
2024.
Since the announcement of the
programme, the following transactions have been made:
| |
Number
of B shares
(of DKK 0.10) | | |
Average
purchase price | | |
Transaction
value,
DKK | |
Accumulated, last announcement | |
| 440,000 | | |
| | | |
| 310,784,175 | |
13 November 2023 | |
| 110,000 | | |
| 708.41 | | |
| 77,924,787 | |
14 November 2023 | |
| 113,000 | | |
| 692.59 | | |
| 78,263,126 | |
15 November 2023 | |
| 113,000 | | |
| 676.25 | | |
| 76,416,161 | |
16 November 2023 | |
| 110,000 | | |
| 678.91 | | |
| 74,679,694 | |
17 November 2023 | |
| 110,000 | | |
| 694.32 | | |
| 76,374,652 | |
Accumulated under the
programme | |
| 996,000 | | |
| | | |
| 694,442,596 | |
The details for each
transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to
Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 134,052 B shares in the period from 7
November 2023 to 16 November 2023. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions
stated above, Novo Nordisk owns a total of 49,000,054 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share
capital. The total amount of A and B shares of DKK 0.10 in the company is 4,510,000,000 including treasury shares.
Novo Nordisk expects to
repurchase B shares for an amount up to DKK 30 billion during a 12- month period beginning 1 February 2023. As of 17 November 2023, Novo
Nordisk has since 1 February 2023 repurchased a total of 45,103,778 B shares of DKK 0.10 at an average share price of DKK 589.08 per
B share of DKK 0.10 equal to a transaction value of DKK 26,569,527,394.
Novo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases,
built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working
to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information |
|
|
|
Media: |
|
Ambre James-Brown |
Elizabeth DeLuca (US) |
+45 3079 9289 |
+1 609 580 9868 |
abmo@novonordisk.com |
edel@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen |
Jacob Martin Wiborg Rode |
+45 3075 2175 |
+45 3075 5956 |
dabo@novonordisk.com |
jrde@novonordisk.com |
|
|
David Heiberg Landsted |
Mark Joseph Root (US) |
+45 3077 6915 |
+1 848 213 3219 |
dhel@novonordisk.com |
mjhr@novonordisk.com |
|
|
Sina Meyer |
Frederik Taylor Pitter |
+45 3075 6656 |
+45 3075 8259 |
azey@novonordisk.com |
fptr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 79 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 20, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024